Accelerating Clinical Trials in the European Union (ACT-EU)
The Multistakeholder Platform (MSP) and the position of the European Industrial Pharmacists Group (EIPG) by Rebecca Rebecca Stanbrook…
EMA’s recommendations to prevent medicines shortages
By Giuliana Miglierini Continuity of medicinal product supply is still representing a key issue for European countries. The…
The new MHRA’s framework for clinical studies
By Giuliana Miglierini The repositioning of the United Kingdom as a global leader for clinical development of medicinal…
The EU Commission proposal of the new pharmaceutical legislation
By Giuliana Miglierini After a five-months delay, the European Commission has announced on 26 April 2023 its proposal…
Current inspection trends and new approaches to the monitoring of post-inspection activities
by Giuliana Miglierini The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published its Annual Regulatory GMP/GDP…
EMA’s consultation on draft Q&As on remote certification of batches by QP
by Giuliana Miglierini The last two years saw the implementation of a high degree of regulatory flexibility as…